Clonal hematopoiesis of indeterminate potential (CHIP) — age-related mutations in blood stem cells — increases disease risk across seven organ systems among 431,546 UK Biobank participants. CHIP carriers showed 14% higher cancer risk, 12% increased infection rates, and elevated risks for blood disorders (31% increase), respiratory diseases (10%), and nervous system conditions (5%). TET2 mutations proved most harmful among CHIP variants, while larger clone sizes conferred greater risks than smaller mutations. The interaction between CHIP and shortened telomeres amplified disease susceptibility, particularly for cardiovascular mortality (19% increase). This comprehensive analysis positions CHIP as a measurable aging biomarker with broad health implications. Unlike traditional genetic risk factors that target specific diseases, CHIP represents systemic aging acceleration affecting multiple organ systems simultaneously. The findings suggest that detecting CHIP mutations could identify individuals at elevated risk decades before symptoms appear, potentially enabling targeted interventions. However, the observational design cannot establish causation, and the predominantly white UK population limits generalizability. As CHIP detection becomes more accessible through genetic testing, understanding its multi-system impact becomes crucial for personalized aging and disease prevention strategies.